- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Lee Schwartzberg on the Exclusion of Men From BRCA Screening Recommendations
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses exclusion of men from the US Preventive Services Task Force's (USPSTF's) updated BRCA screening recommendation update.
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses exclusion of men from the US Preventive Services Task Force's (USPSTF's) updated BRCA screening recommendation update.
Transcript
What are your thoughts on USPSTF leaving men out of its updated recommendation for BRCA1/2 screening and testing?
Well, I believe that all men who have breast cancer, for example, should be tested. About 10% of them will have a hereditary, usually a BRCA 1 or 2 gene. The number of genes that contribute to hereditary breast or ovarian cancer is broadening over time, and so we’re learning more over time as we move from the very high penetrant cancer syndromes to somewhat less, but we’re learning a lot, so I think men will be included in the near future.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
